Actively Recruiting
Nab-paclitaxel Versus Sb-taxanes As First-Line Treatment in Advanced Ovarian Cancer
Led by Women's Hospital School Of Medicine Zhejiang University · Updated on 2025-02-11
538
Participants Needed
11
Research Sites
213 weeks
Total Duration
On this page
Sponsors
W
Women's Hospital School Of Medicine Zhejiang University
Lead Sponsor
J
Jiaxing Maternity and Child Health Care Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose of this study is to compare the efficacy and safety of nab-paclitaxel with solvent-based taxanes as first-line treatment for patients with advanced primary epithelial ovarian cancer (EOC), primary peritoneal carcinoma or fallopian tube carcinoma.
CONDITIONS
Official Title
Nab-paclitaxel Versus Sb-taxanes As First-Line Treatment in Advanced Ovarian Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with epithelial ovarian cancer, tubal cancer, or peritoneal cancer, classified as stage III-IV by FIGO
- Eastern Cooperative Oncology Group PS score between 0 and 2
- No participation in other drug clinical trials within 4 weeks before enrollment
- Provided written informed consent
- Expected survival of 6 months or more
- Disease meets criteria for solid tumor evaluation (RECIST 1.1)
- Able to follow outpatient treatment, lab tests, and clinical visits during the study
You will not qualify if you...
- Diagnosis of low malignant potential ovarian tumors
- History of other malignant tumors in the past 5 years except cured cervical carcinoma in situ or non-melanoma skin cancer
- Previous chemotherapy or radiotherapy to the pelvic cavity
- Central nervous system metastasis or peripheral neuropathy greater than grade 1
- Severe myelosuppression, severe liver dysfunction (Child's Class III), or renal dysfunction at screening
- Severe cardiovascular disease including Grade I or higher myocardial ischemia or infarction, poorly controlled arrhythmias, NYHA grade II to III heart failure, or low left ventricular ejection fraction
- Uncontrolled systemic infection needing anti-infective treatment
- Arteriovenous thrombosis events within 6 months before randomization
- Allergy to albumin paclitaxel or carboplatin
- Pregnant or breastfeeding women
- Considered unsuitable for the study by researchers
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 11 locations
1
Sun Yat-Sen University Cancer Hospital
Guangzhou, Guangdong, China
Not Yet Recruiting
2
Qilu Hospital of Shandong University
Ji'nan, Shandong, China, 250012
Not Yet Recruiting
3
Yaxia Chen
Hangzhou, Zhejiang, China, 310006
Actively Recruiting
4
Sir Run Run Hospital
Hangzhou, Zhejiang, China
Not Yet Recruiting
5
The First Affiliated Hospital of Medical College of Zhejiang University
Hangzhou, Zhejiang, China
Not Yet Recruiting
6
The Second Affiliated Hospital of Medical College of Zhejiang University
Hangzhou, Zhejiang, China
Not Yet Recruiting
7
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China
Not Yet Recruiting
8
Ningbo women's and children's Hospital
Ningbo, Zhejiang, China
Not Yet Recruiting
9
The No, 1 People's Hospital of Ningbo
Ningbo, Zhejiang, China
Not Yet Recruiting
10
The Second Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, China
Not Yet Recruiting
11
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, China
Not Yet Recruiting
Research Team
Y
Yaxia Chen, MD
CONTACT
Y
Yang Li, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
OTHER
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here